Text Size

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00546624
First received: October 17, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
  Purpose

This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Anxiety Disorder
 Drug: MK0777
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date: November 2002
Study Completion Date: December 2003
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have been diagnosed with Generalized Anxiety Disorder
  • Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study

Exclusion Criteria:

  • History of drug or alcohol abuse
  • Have previously participated in another study using MK0777
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00546624

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00546624     History of Changes
Other Study ID Numbers: 2007_632
Study First Received: October 17, 2007
Last Updated: October 17, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on June 18, 2013